Oncology
Early Lung Cancer Just Became a Biomarker Test of the System
New Phase III ELEVATE data published in NEJM show adjuvant ensartinib sharply reduced recurrence risk after resection in ALK-positive NSCLC. The science is clear. The access question is whether early-stage lung cancer pathways can test fast enough to use it.
ASCO 2026: AI is entering cancer care before the rules are ready
ASCO 2026: Are we overtreating cancer?
ASCO 2026: Why oncology is also paying attention to GLP-1 medicines
Regulators Start Writing the Rules for AI-Driven Medicines
AI Pathology Moves From Demo to Workflow
FDA Puts AI Inside the Evidence Machine
AlphaGenome Makes Variant Interpretation Political
AI Diagnosis Has Entered the Access Debate
Oncology Trials Still Do Not Match the Patients They Will Treat
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.